Therapeutics News and Research

RSS

Eli Lilly’s Adverum move: The future of ocular gene therapy at the 4th Ophthalmic Drug Delivery Summit

The race to develop safer, longer lasting, and less invasive treatments is accelerating, and at the heart of that challenge lies drug delivery.

From Hanson Wade Group - 4th Ophthalmic Drug Delivery Summit 26 Nov 2025

Experimental drug engasertib shows promise for treating inherited bleeding disorder

Hereditary hemorrhagic telangiectasia (HHT) is the second most common inherited bleeding disorder worldwide, affecting 1 in 3,800 persons.

26 Nov 2025

Comprehensive research identifies most effective ADHD treatments

The most comprehensive review to date of ADHD treatments has found that medication for children and adults, and cognitive behavioral therapy for adults, remain the most effective approaches, backed by the strongest short-term trial evidence.

26 Nov 2025

UBQLN2 liquid droplets emerge as key catalysts of early α-synuclein aggregation

Parkinson's disease (PD) is an age-related, progressive neurodegenerative disorder. The hallmark of PD pathogenesis is the Lewy bodies (LBs) that accumulate in neurons in the substantia nigra region of the brain, damaging these neurons and leading to the motor symptoms of the disease.

26 Nov 2025

Novel mRNA-based therapy may offer a new path to tackle antibiotic-resistant infections

Researchers at the Icahn School of Medicine at Mount Sinai and collaborators have reported early success with a novel mRNA-based therapy designed to combat antibiotic-resistant bacteria.

26 Nov 2025

'Myeloid mimicry' identified as driver of immunotherapy resistance in renal medullary carcinoma

Researchers at The University of Texas MD Anderson Cancer Center have found that renal medullary carcinoma (RMC) cells use an adaptive mechanism called "myeloid mimicry" to hide from the immune system and promote disease hyper progression after immunotherapy, highlighting specific targets that overcome treatment resistance in preclinical models.

25 Nov 2025

Zanidatamab shows durable and meaningful responses in HER2-positive biliary tract cancer

Zanidatamab, a bispecific HER2-targeted antibody, delivered clinically meaningful and durable responses for patients with HER2-positive biliary tract cancer (BTC), according to final results from the HERIZON-BTC-01 clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

25 Nov 2025

Study elucidates how anti-amyloid antibody therapy lecanemab works in Alzheimer's disease

Lecanemab, sold under the name Leqembi, is a monoclonal antibody therapy for Alzheimer's disease that clears toxic amyloid plaques and delays cognitive decline.

25 Nov 2025

New skin-permeable polymer delivers insulin without needles

Innovative zwitterionic polymer facilitates insulin absorption through the skin, offering a painless alternative to injections for diabetes management.

25 Nov 2025

Unraveling the mycobiome's role in cancer

A growing body of evidence indicates that the microbiome within the gut and tumors significantly influences cancer initiation, progression, and treatment response.

25 Nov 2025

Focused ultrasound combined with chemotherapy improves survival in glioblastoma patients

Patients with the deadliest form of brain cancer, glioblastoma, who received MRI-guided focused ultrasound with standard-of-care chemotherapy had a nearly 40 percent increase in overall survival in a landmark trial of 34 patients led by University of Maryland School of Medicine (UMSOM) researchers.

24 Nov 2025

Scientists reverse aging in blood stem cells by restoring lysosome function

Researchers at the Icahn School of Medicine at Mount Sinai have discovered how to reverse aging in blood-forming stem cells in mice by correcting defects in the stem cell's lysosomes.

24 Nov 2025

Intranasal nanomedicine shows promise against glioblastoma

Researchers at Washington University School of Medicine in St. Louis, along with collaborators at Northwestern University, have developed a noninvasive approach to treat one of the most aggressive and deadly brain cancers.

22 Nov 2025

Research explores new solvent strategies to extend shelf life of injectable therapeutics

Sugar-based liquid solvents store crucial injection-based therapeutics such as insulin and vaccines.

22 Nov 2025

New signaling molecule drives development of tissue resident memory T cells

We owe a lot to tissue resident memory T cells (TRM). These specialized immune cells are among the body's first responders to disease.

22 Nov 2025

Comprehensive antibody map reveals how SARS-CoV-2 mutations evade immunity

Researchers at the Icahn School of Medicine at Mount Sinai and collaborators have created the most comprehensive map to date showing how antibodies attach to the SARS-CoV-2 virus, which causes COVID-19, and how viral mutations weaken that attachment.

21 Nov 2025

New funding advances AI-powered technology to track therapeutic and diseased cells

Targeting and treating diseases first requires being able to find specific cells-which is challenging because they travel within the body and can "hide."

21 Nov 2025

Global collaboration accelerates progress toward eliminating cervical cancer

Cervical cancer will be the first human cancer eliminated through coordinated global action. A new special issue of Cancer Biology & Medicine brings together leading experts from around the world to examine progress, challenges, and innovations in prevention, screening, and treatment.

21 Nov 2025

CAR T cell therapy could be a highly effective tool against atherosclerosis

A pioneering preclinical study has shown that CAR T cell therapy-a personalized form of immunotherapy used in cancer treatment-could be a highly effective tool against atherosclerosis, the condition where a build-up of plaque in the arteries reduces blood flow, leading to heart attacks and strokes.

21 Nov 2025

RNA-based cocktail shows promise against glioblastoma

A patented RNA-based cocktail developed at the Italian Institute of Technology (IIT-Istituto Italiano di Tecnologia) has emerged as a promising active agent against tumors of the central nervous system, such as glioblastoma.

20 Nov 2025

Therapeutics News and Research

Eli Lilly’s Adverum move: The future of ocular gene therapy at the 4th Ophthalmic Drug Delivery Summit

Experimental drug engasertib shows promise for treating inherited bleeding disorder

Comprehensive research identifies most effective ADHD treatments

UBQLN2 liquid droplets emerge as key catalysts of early α-synuclein aggregation

Novel mRNA-based therapy may offer a new path to tackle antibiotic-resistant infections

'Myeloid mimicry' identified as driver of immunotherapy resistance in renal medullary carcinoma

Zanidatamab shows durable and meaningful responses in HER2-positive biliary tract cancer

Study elucidates how anti-amyloid antibody therapy lecanemab works in Alzheimer's disease

New skin-permeable polymer delivers insulin without needles

Unraveling the mycobiome's role in cancer

Focused ultrasound combined with chemotherapy improves survival in glioblastoma patients

Scientists reverse aging in blood stem cells by restoring lysosome function

Intranasal nanomedicine shows promise against glioblastoma

Research explores new solvent strategies to extend shelf life of injectable therapeutics

New signaling molecule drives development of tissue resident memory T cells

Comprehensive antibody map reveals how SARS-CoV-2 mutations evade immunity

New funding advances AI-powered technology to track therapeutic and diseased cells

Global collaboration accelerates progress toward eliminating cervical cancer

CAR T cell therapy could be a highly effective tool against atherosclerosis

RNA-based cocktail shows promise against glioblastoma

Industry Focus eBook - Cell biology (5th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News